This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/national-drug-code-directory/
n25http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/patent/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n27http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00658/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00658
rdf:type
n3:Drug
n3:description
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.
n3:dosage
n24:271B63B1-363D-11E5-9242-09173F13E4C5 n24:271B63B2-363D-11E5-9242-09173F13E4C5 n24:271B63B3-363D-11E5-9242-09173F13E4C5 n24:271B63B4-363D-11E5-9242-09173F13E4C5 n24:271B63B0-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
n3:manufacturer
n4:271B63AC-363D-11E5-9242-09173F13E4C5 n4:271B63AB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00658 n25:DB00658
dcterms:title
Sevelamer
adms:identifier
n10:Sevelamer n14:DB00658 n18:2341997 n19:3085017 n20:D01983 n21:PA164781197 n22:58468-0021-3 n23:46505951
n3:mechanismOfAction
Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels.
n3:packager
n4:271B63A2-363D-11E5-9242-09173F13E4C5 n4:271B63A0-363D-11E5-9242-09173F13E4C5 n4:271B63A1-363D-11E5-9242-09173F13E4C5 n4:271B639E-363D-11E5-9242-09173F13E4C5 n4:271B63AA-363D-11E5-9242-09173F13E4C5 n4:271B639F-363D-11E5-9242-09173F13E4C5 n4:271B639C-363D-11E5-9242-09173F13E4C5 n4:271B639D-363D-11E5-9242-09173F13E4C5 n4:271B63A5-363D-11E5-9242-09173F13E4C5 n4:271B63A6-363D-11E5-9242-09173F13E4C5 n4:271B63A3-363D-11E5-9242-09173F13E4C5 n4:271B63A4-363D-11E5-9242-09173F13E4C5 n4:271B63A9-363D-11E5-9242-09173F13E4C5 n4:271B63A7-363D-11E5-9242-09173F13E4C5 n4:271B63A8-363D-11E5-9242-09173F13E4C5
n3:patent
n11:5496545 n11:2169356 n11:6733780 n11:2310960
n3:synonym
Sevelamero Sevelamer Renagel Sévélamer Sevelamerum
n3:toxicity
Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
n16:hasAHFSCode
n17:92-00-00
n3:salt
n3:synthesisReference
Deepak Anant Hedge, Varsha Shashank Choudhary, Venkatasubramanian Radhakrjshnan Tarur, Dhananjay Govind Sathe, Harish Kashinath Mondkar, Samadhan Daulat Patil, Sasikumar Mohan Thoovara, Yogesh Sharad Bhide, "Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof." U.S. Patent US20090280178, issued November 12, 2009.
foaf:page
n8:sevelamer.html n27:sevel.htm
n3:IUPAC-Name
n5:271B63B6-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B63BC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B63BB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B63B8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B63B9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B63BA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B63CB-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B63B5-363D-11E5-9242-09173F13E4C5 n5:271B63CC-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n26:V03AE02
n3:H-Bond-Acceptor-Count
n5:271B63C2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B63C3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B63BD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B63BE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B63C0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B63BF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B63C1-363D-11E5-9242-09173F13E4C5
n3:absorption
Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
152751-57-0
n3:containedIn
n6:271B63AF-363D-11E5-9242-09173F13E4C5 n6:271B63AD-363D-11E5-9242-09173F13E4C5 n6:271B63AE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B63C7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B63C9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B63CA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B63C6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B63C5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B63C8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B63B7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B63C4-363D-11E5-9242-09173F13E4C5